Asceneuron SA

Asceneuron Secures $100m Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA...
Asceneuron SA, EPFL Innovation Park, Bâtiment B, CH-1015 Lausanne, Switzerland